SETD2 variation correlates with tumor mutational burden and MSI along with improved response to immunotherapy

[1]  Y. Bang,et al.  Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. , 2020, The Lancet. Oncology.

[2]  R. Vaclavikova,et al.  DNA Repair and Ovarian Carcinogenesis: Impact on Risk, Prognosis and Therapy Outcome , 2020, Cancers.

[3]  G. Shapiro,et al.  Biomarker-Guided Development of DNA Repair Inhibitors. , 2020, Molecular cell.

[4]  M. Ji,et al.  Histone methyltransferase SETD2: a potential tumor suppressor in solid cancers , 2020, Journal of Cancer.

[5]  X. Yi,et al.  Association of Tumor Protein p53 and Ataxia-Telangiectasia Mutated Comutation With Response to Immune Checkpoint Inhibitors and Mortality in Patients With Non–Small Cell Lung Cancer , 2019, JAMA network open.

[6]  Ahmet Zehir,et al.  Genetic diversity of tumors with mismatch repair deficiency influences anti–PD-1 immunotherapy response , 2019, Science.

[7]  Z. Pursell,et al.  POLE proofreading defects: Contributions to mutagenesis and cancer. , 2019, DNA repair.

[8]  C. Brennan,et al.  Tumor mutational load predicts survival after immunotherapy across multiple cancer types , 2019, Nature Genetics.

[9]  C. Hutter,et al.  The Cancer Genome Atlas: Creating Lasting Value beyond Its Data , 2018, Cell.

[10]  Steven J. M. Jones,et al.  Comprehensive Characterization of Cancer Driver Genes and Mutations , 2018, Cell.

[11]  Li Ding,et al.  Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics , 2018, Cell.

[12]  L. Gu,et al.  H3K36me3-mediated mismatch repair preferentially protects actively transcribed genes from mutation , 2018, The Journal of Biological Chemistry.

[13]  Steven J. M. Jones,et al.  The Immune Landscape of Cancer , 2018, Immunity.

[14]  Jedd D. Wolchok,et al.  Cancer immunotherapy using checkpoint blockade , 2018, Science.

[15]  K. Cole,et al.  Comprehensive Analysis of Hypermutation in Human Cancer , 2017, Cell.

[16]  Russell Bonneville,et al.  Landscape of Microsatellite Instability Across 39 Cancer Types. , 2017, JCO precision oncology.

[17]  D. Schadendorf,et al.  Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma , 2017, The New England journal of medicine.

[18]  Ludmila V. Danilova,et al.  Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade , 2017, Science.

[19]  Michael S. Goldberg,et al.  DNA Damage and Repair Biomarkers of Immunotherapy Response. , 2017, Cancer discovery.

[20]  Donavan T. Cheng,et al.  Mutational Landscape of Metastatic Cancer Revealed from Prospective Clinical Sequencing of 10,000 Patients , 2017, Nature Medicine.

[21]  D. Schadendorf,et al.  Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  M. Atkins,et al.  Predictive biomarkers for checkpoint inhibitor-based immunotherapy. , 2016, The Lancet. Oncology.

[23]  J. Radford.  Nivolumab for recurrent squamous-cell carcinoma of the head and neck , 2016, BDJ.

[24]  S. Spranger.  Mechanisms of tumor escape in the context of the T-cell-inflamed and the non-T-cell-inflamed tumor microenvironment. , 2016, International immunology.

[25]  E. Golemis,et al.  POLD1: Central mediator of DNA replication and repair, and implication in cancer and other pathologies , 2016, Gene.

[26]  J. Lunceford,et al.  Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. , 2016, The Lancet. Oncology.

[27]  Gyan Bhanot,et al.  Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer. , 2016, The Journal of clinical investigation.

[28]  Y. Shentu,et al.  Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial , 2016, The Lancet.

[29]  A. Ravaud,et al.  Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. , 2015, The New England journal of medicine.

[30]  M. Valsecchi.  Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. , 2015, The New England journal of medicine.

[31]  T. Barnetche,et al.  Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis , 2015, BMC Medicine.

[32]  G. Linette,et al.  Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. , 2015, The Lancet. Oncology.

[33]  S. Sarkar,et al.  SETD2-Dependent Histone H3K36 Trimethylation Is Required for Homologous Recombination Repair and Genome Stability , 2014, Cell reports.

[34]  J. Desterro,et al.  SETD2 is required for DNA double-strand break repair and activation of the p53-mediated checkpoint , 2014, eLife.

[35]  Kai Ye,et al.  MSIsensor: microsatellite instability detection using paired tumor-normal sequence data , 2014, Bioinform..

[36]  Jennifer Couzin-Frankel,et al.  Breakthrough of the year 2013. Cancer immunotherapy. , 2013, Science.

[37]  Peter J. Park,et al.  The Landscape of Microsatellite Instability in Colorectal and Endometrial Cancer Genomes , 2013, Cell.

[38]  G. Getz,et al.  Inferring tumour purity and stromal and immune cell admixture from expression data , 2013, Nature Communications.

[39]  Wei Yang,et al.  The Histone Mark H3K36me3 Regulates Human DNA Mismatch Repair through Its Interaction with MutSα , 2013, Cell.

[40]  Colin N. Dewey,et al.  RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome , 2011, BMC Bioinformatics.

[41]  R. Schreiber,et al.  Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion , 2011, Science.

[42]  Gurpreet W. Tang,et al.  Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes , 2009, Nature.

[43]  Ben S. Wittner,et al.  Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1 , 2009, Nature.

[44]  A. Ashworth,et al.  Hallmarks of 'BRCAness' in sporadic cancers , 2004, Nature Reviews Cancer.

[45]  D. Kennedy.  Breakthrough of the Year , 2004, Science.

[46]  Ash A. Alizadeh,et al.  SUPPLEMENTARY NOTE , 1879, Botanical Gazette.

[47]  Vanessa M. Hubbard-Lucey,et al.  Comprehensive analysis of the clinical immuno-oncology landscape , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[48]  J. Wolchok,et al.  Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. , 2015, The New England journal of medicine.

[49]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[50]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[51]  J. D. de Bono,et al.  Parp Inhibitors , 2022 .